An LNM-Associated Gene Signature for Prognostic Prediction and Immune Profiling in Head and Neck Squamous Cell Carcinoma.

IF 2.4 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2025-06-01 Epub Date: 2025-03-11 DOI:10.1089/cbr.2024.0147
Zhenzhen Wang, Zhenhua Wu, Lixin Cheng, Qi Huang, Jian Zhang, Yuan Ren, Juntao Huang, Yi Shen
{"title":"An LNM-Associated Gene Signature for Prognostic Prediction and Immune Profiling in Head and Neck Squamous Cell Carcinoma.","authors":"Zhenzhen Wang, Zhenhua Wu, Lixin Cheng, Qi Huang, Jian Zhang, Yuan Ren, Juntao Huang, Yi Shen","doi":"10.1089/cbr.2024.0147","DOIUrl":null,"url":null,"abstract":"<p><p>Lymph node metastasis (LNM) plays a critical role in the prognosis of head and neck squamous cell carcinoma (HNSCC). To enhance prognostic predictions and investigate the molecular interplay between LNM and HNSCC, we developed an LNM-associated gene signature. Data was sourced from The Cancer Genome Atlas (TCGA), encompassing RNA-sequencing and clinical profiles. We stratified patients based on LNM status and identified differentially expressed genes (DEGs) between lymph node-negative (N0) and lymph node-positive (N1-3) groups. A prognostic model was then constructed while employing Least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses. Patients were randomly allocated into training (70%) and internal validation (30%) cohorts, with an additional external dataset used for validation. The predictive model's performance was assessed through receiver operating characteristic curves and survival analyses. We identified 79 LNM-related prognostic DEGs that formed the basis of our LNM-related risk score (LNMRS). This score stratified patients into low- and high-risk categories, with those having lower LNMRS exhibiting improved survival outcomes, increased immune cell infiltration, and enhanced responses to immunotherapy (PD-1/CTLA4 inhibitors) and chemotherapy. In contrast, patients with high LNMRS showed poorer prognosis and reduced immune responsiveness. Our LNM-related model provides insights into the molecular mechanisms linking LNM and HNSCC and offers a promising tool for personalized treatment strategies. This approach underscores the potential of integrating LNM status with gene expression profiles to refine prognosis and optimize therapeutic interventions in HNSCC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"339-351"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2024.0147","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Lymph node metastasis (LNM) plays a critical role in the prognosis of head and neck squamous cell carcinoma (HNSCC). To enhance prognostic predictions and investigate the molecular interplay between LNM and HNSCC, we developed an LNM-associated gene signature. Data was sourced from The Cancer Genome Atlas (TCGA), encompassing RNA-sequencing and clinical profiles. We stratified patients based on LNM status and identified differentially expressed genes (DEGs) between lymph node-negative (N0) and lymph node-positive (N1-3) groups. A prognostic model was then constructed while employing Least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses. Patients were randomly allocated into training (70%) and internal validation (30%) cohorts, with an additional external dataset used for validation. The predictive model's performance was assessed through receiver operating characteristic curves and survival analyses. We identified 79 LNM-related prognostic DEGs that formed the basis of our LNM-related risk score (LNMRS). This score stratified patients into low- and high-risk categories, with those having lower LNMRS exhibiting improved survival outcomes, increased immune cell infiltration, and enhanced responses to immunotherapy (PD-1/CTLA4 inhibitors) and chemotherapy. In contrast, patients with high LNMRS showed poorer prognosis and reduced immune responsiveness. Our LNM-related model provides insights into the molecular mechanisms linking LNM and HNSCC and offers a promising tool for personalized treatment strategies. This approach underscores the potential of integrating LNM status with gene expression profiles to refine prognosis and optimize therapeutic interventions in HNSCC.

一个用于头颈部鳞状细胞癌预后预测和免疫谱的lnm相关基因标记。
淋巴结转移(LNM)在头颈部鳞状细胞癌(HNSCC)的预后中起着关键作用。为了加强预后预测和研究LNM与HNSCC之间的分子相互作用,我们开发了LNM相关基因标记。数据来自癌症基因组图谱(TCGA),包括rna测序和临床资料。我们根据淋巴结转移情况对患者进行分层,并鉴定淋巴结阴性(N0)组和淋巴结阳性(N1-3)组之间的差异表达基因(DEGs)。然后采用最小绝对收缩和选择算子(LASSO)和多变量Cox回归分析构建预后模型。患者被随机分配到训练(70%)和内部验证(30%)队列中,并使用额外的外部数据集进行验证。通过受试者工作特征曲线和生存分析评估预测模型的性能。我们确定了79个与lnm相关的预后deg,这些deg构成了lnm相关风险评分(LNMRS)的基础。该评分将患者分为低风险和高风险两类,LNMRS较低的患者表现出更好的生存结果,免疫细胞浸润增加,对免疫治疗(PD-1/CTLA4抑制剂)和化疗的反应增强。相反,LNMRS高的患者预后较差,免疫反应性降低。我们的LNM相关模型为LNM和HNSCC之间的分子机制提供了深入的见解,并为个性化治疗策略提供了一个有前途的工具。该方法强调了将LNM状态与基因表达谱结合起来改善HNSCC预后和优化治疗干预的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.80
自引率
2.90%
发文量
87
审稿时长
3 months
期刊介绍: Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信